Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Bristol-Myers Squibb’s immunotherapy combination treatment Opdivo (nivolumab) plus Yervoy (ipilimumab) improved survival in patients with previously untreated, malignant pleural mesothelioma (MPM).